Novavax Inc: A Safe Investment Bet?

Novavax, Inc. is a biotechnology company that was founded in 1987 and is headquartered in Gaithersburg, MD. The company engages in the discovery, development, and commercialisation of recombinant vaccines. In this article, we will explore whether Novavax, Inc. is a safe investment by considering various factors such as market data, investment objectives, and risk appetite. We will also discuss the potential risks and costs associated with investing in the financial markets.

Novavax's history and headquarters

Novavax, Inc. is a biotechnology company that was founded in 1987 and is headquartered in Gaithersburg, MD. The company engages in the discovery, development, and commercialisation of recombinant vaccines. Novavax has a history of developing innovative vaccines and has a strong track record of bringing new products to market.

Over the years, Novavax has established itself as a leader in the biotechnology industry, with a focus on recombinant vaccines. Recombinant vaccines are created by combining DNA from multiple sources to produce a vaccine that can protect against multiple diseases. This technology has allowed Novavax to develop a range of effective and safe vaccines.

The company's history of innovation and success has made it a trusted name in the industry. Novavax has a strong reputation for its scientific expertise and commitment to bringing life-saving vaccines to market. The company's headquarters in Gaithersburg, MD, serves as a hub for its research and development activities, with state-of-the-art facilities and a team of experienced scientists and researchers.

Novavax's headquarters in Gaithersburg, MD, is also home to its executive team and corporate functions. The company has a strong presence in the local community and is committed to supporting local initiatives and organisations. Novavax has a history of partnering with local schools and universities to promote STEM education and has established scholarships and internships to support the next generation of scientists and researchers.

Overall, Novavax's history and headquarters reflect a company that is committed to innovation, scientific excellence, and community engagement. With a strong track record of success and a focus on recombinant vaccine technology, Novavax has established itself as a leader in the biotechnology industry.

Novavax's stock price

Novavax Inc. is a biotechnology company that engages in the discovery, development, and commercialisation of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland.

On Thursday 20 March 2025, Novavax Inc. shares started trading at $7.82. This was a drop of 1.08% from the previous day's closing price of $7.91. There are 160.84 million shares outstanding in Novavax Inc., which values the company at $1.12 billion. Novavax stock has received a consensus rating of 'buy'. The average rating score is based on four buy ratings, two hold ratings, and one sell rating.

The median target price forecast for Novavax is $20.86, with a high estimate of $35 and a low estimate of $8. The median estimate represents a 37.30% difference from the last price of $7.78. The high in the last 52 weeks of Novavax stock was $26.19, and the low was $3.81. According to the current price, Novavax is 29.71% away from the 52-week high and 204.20% away from the 52-week low.

Novavax's industry peers

Novavax, Inc. is a biotechnology company that was founded in 1987 and is headquartered in Gaithersburg, MD. The company engages in the discovery, development, and commercialisation of recombinant vaccines.

Some of the key industry peers for Novavax may include:

• Moderna, Inc.: Moderna is a biotechnology company that has gained prominence during the COVID-19 pandemic due to its mRNA vaccine. Moderna has a similar business model to Novavax, focusing on vaccine development and commercialisation.
• Pfizer, Inc.: Pfizer is a well-known pharmaceutical company that has also been at the forefront of the COVID-19 vaccine race. Pfizer has a diverse portfolio of products and a strong presence in the industry.
• BioNTech SE: BioNTech is a German biotechnology company that collaborated with Pfizer on the development and commercialisation of their COVID-19 vaccine. BioNTech has a strong focus on immunotherapy and personalised medicine.
• Johnson & Johnson: Johnson & Johnson is a diversified healthcare company with a presence in the vaccine market. They have developed a single-dose COVID-19 vaccine and have a broad portfolio of healthcare products.

These industry peers may offer a benchmark for comparing Novavax's performance, business model, and investment potential. It is important to note that the performance of Novavax may not necessarily mirror that of its industry peers, and individual company fundamentals, performance metrics, and investor preferences should also be considered when evaluating investment opportunities.

Novavax's investment metrics

Novavax, Inc. is a biotechnology company that was founded in 1987 and is headquartered in Gaithersburg, MD. The company engages in the discovery, development, and commercialisation of recombinant vaccines.

• The company is compared to its industry peers based on a variety of company fundamentals, performance metrics, and investor preferences.
• Market data is provided by Xignite, and fund data is provided by Xignite and Morningstar.
• The prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory, or political events.
• Trading on margin increases financial risks, and investors should carefully consider their investment objectives, level of experience, and risk appetite before trading.
• The data and prices on the website may not always be accurate and may differ from the actual price at any given market, so prices are indicative and not appropriate for trading purposes.

Novavax's investment risks

Novavax Inc. is a biotechnology company that engages in the discovery, development, and commercialisation of recombinant vaccines.

There are several risks associated with investing in Novavax. Firstly, the company's stock price has been volatile, with daily average volatility of 5.96% over the last week. Secondly, Novavax holds several negative signals and is within a very wide and falling trend, indicating that it will likely perform weakly in the next couple of days or weeks. Thirdly, a sell signal was issued on March 17, 2025, and the stock has since fallen by 5.61%. Finally, trading in financial instruments and cryptocurrencies involves high risks, including the possibility of losing some or all of your investment.

Therefore, investors should carefully consider their investment objectives, level of experience, and risk appetite before investing in Novavax.

Frequently asked questions